Cindy Sander

List of Publications by Year
in descending order

15 papers	2,724 citations	686830 13 h-index	996533 15 g-index
15 all docs	15 docs citations	15 times ranked	5050 citing authors

#	Article	IF	Citations
1	Tim-3 mediates T cell trogocytosis to limit antitumor immunity. Journal of Clinical Investigation, 2022, 132, .	3.9	25
2	Predicting Metastasis in Melanoma by Enumerating Circulating Tumor Cells Using Photoacoustic Flow Cytometry. Lasers in Surgery and Medicine, 2021, 53, 578-586.	1.1	10
3	Neoadjuvant Pembrolizumab and High-Dose IFNÎ±-2b in Resectable Regionally Advanced Melanoma. Clinical Cancer Research, 2021, 27, 4195-4204.	3.2	18
4	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clinical Cancer Research, 2020, 26, 5520-5533.	3.2	88
5	Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, GÎ±_q and GÎ±₁₁ and kill uveal melanoma cells. Cancer Biology and Therapy, 2019, 20, 700-710.	1.5	37
6	Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight, 2019, 4, .	2.3	148
7	The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biology and Therapy, 2018, 19, 132-137.	1.5	32
8	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. Journal of Clinical Oncology, 2018, 36, 3450-3458.	0.8	55
9	CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight, 2018, 3, .	2.3	137
10	Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. OncoImmunology, 2017, 6, e1231291.	2.1	29
11	The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget, 2017, 8, 16367-16386.	0.8	55
12	TIGIT and PD-1 impair tumor antigenâ€“specific CD8+ T cells in melanoma patients. Journal of Clinical Investigation, 2015, 125, 2046-2058.	3.9	603
13	Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab. PLoS ONE, 2014, 9, e87705.	1.1	261
14	Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenâ€“specific CD8+ T cell dysfunction in melanoma patients. Journal of Experimental Medicine, 2010, 207, 2175-2186.	4.2	1,118
15	Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients. Journal of Immunotherapy, 2008, 31, 781-791.	1.2	108